Top Biotech Stocks To Watch After Bristol Myers' Opdivo Sees Q2 Growth

Hot biotech stocks to watch right now as cancer treatments make headlines in 2021.


This story originally appeared on PennyStocks

Cancer Stocks Are In Focus After Big News From Merck & Bristol-Myers This Week

Just one day after Merck’s (NYSE:MRK) blockbuster FDA approval news, Bristol-Myers Squibb (NYSE:BMY) added more fuel to the fire. Cancer treatments have remained a hotbed for biotech companies. Now the R&D from years past seems to have begun paying off. Wednesday morning Bristol-Myers reported its second-quarter earnings.

After dissecting the data, there are several significant things to take away from these results. First, the biotech company is back to growth. The company reported an increase of 16% year-over-year in quarterly revenue with $11.7 billion. What’s more, important to understand is the key driver of this growth.

According to its report, Bristol-Myers cited strong performance thanks, in part, to its breakthrough cancer drug, Opdivo, returning to growth. It was further bolstered by momentum across its new product portfolio. This news comes only 1 day after Merck & Co. announced a new advancement for its cancer treatment, Keytruda. The watershed moment for the company saw its novel drug achieved its 30th approved indication in the U.S.

What Does This Mean For Cancer Stocks?

It doesn’t appear to be a coincidence that these milestones in cancer drug advancement are spurring more interest. Take a look at other companies developing oncology pipelines, and you might see a similar bullish trend. Novartis’ (NYSE:NVS) recent uptick in trading has piggybacked off momentum in cancer stocks. This week, the company reported news of its own after gaining FDA Orphan Drug Designation for its NIS793. This drug is being studied in pancreatic cancer. The ODD was granted for NIS793 combined with the current standard of care in patients.

Meanwhile, BioNTech (NASDAQ:BNTX) shifted from COVID to cancer earlier this month after its latest treatment acquisition from Gilead’s (NASDAQ:GILD) Kite subsidiary. BioNTech acquired Kite’s neoantigen TCR cell therapy R&D platform along with its Maryland-based manufacturing facility.

“The development of individualized cancer therapies is at the core of our work at BioNTech. The acquisition of the Kite facility and its individualized TCR platform allows us to accelerate the clinical development of our cell therapies in the U.S. and advance at the forefront of individualized cell therapies.”

Ugur Sahin, M.D., CEO and Co-founder of BioNTech

Not to mention, you’ve also got major M&A deals going on this year showing how valuable oncology treatment pipelines are right now. For instance, Amgen (NASDAQ:AMGN) acquired Five Prime Therapeutics for roughly $1.9 billion. The deal gives Amgen direct access to Five Prime’s oncology portfolio, including a Phase 3 trial-ready gastric cancer treatment.

Top Biotech Stocks To Watch

So what is next for cancer and biotech stocks? Considering these trends and an appetite for billion-dollar M&A, the market seems anxious to find companies with robust oncology treatment pipelines. In this article, we’ll discuss a few more cancer stocks to watch that have begun to catch attention in the stock market this year:

  1. GT Biopharma Inc. (NASDAQ:GTBP)
  2. Fate Therapeutics (NASDAQ:FATE)
  3. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

GT Biopharma Inc. (NASDAQ: GTBP)

One of the hallmarks of the biotech industry is the ability of companies to develop novel treatment pipelines. Many companies look to make a better functioning version of a drug. Others, however, focus on creating a better drug or drug delivery technology altogether. In this case, GT Biopharma has focused on doing just that. The advancements in immunotherapy and targeted cancer medicine have opened a whole new world of opportunities.

If you read the article yesterday, “Biotech Stocks Are In Focus After Merck’s FDA Approval,” we discussed the evolution of cancer treatment from blanketed chemotherapy to individually customized medicines. Natural Killer or “NK” cells have become a key aspect of this “evolutionary” process. In this case, NK cells can be created to trigger certain immune responses in various patients. These cells “identify” cancer cells on their own or in combination with other treatment platforms.

GT Biopharma Inc. (NASDAQ:GTBP) has taken NK cell treatment a step further. The company’s tri-specific natural killer engager treatment platform or “TriKETM” has become the backbone of a robust pipeline of treatment candidates. TriKETM therapy combines proteins that bridge an immune cell and a tumor cell and then exponentially drive tumor cell killing power. It has led to new first-in-human phase studies to treat leukemia and is being studied in other cancers, including breast, lung, gastric, colorectal, and ovarian indications.

GT Biopharma’s Oncology Treatment Platform

GTB-3550 is the first TriKE™ candidate under development to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). This treatment is currently in Phase I/II clinical trials and has already shown meaningful results in the first set of patients undergoing treatment. Currently, 12 patients are enrolled in the trial, with 11 having reported data. GT Biopharma has already shown that initial study results have shown that 57% of patients experiencing “significant reduction in AML/MDS cancer cell burden” when treated with GTB-3550. The safety portion of the Phase 1 study is expected to be completed in late August, with a data publication scheduled for the end of September.

This week, the company announced that it raised over $16 million in proceeds from the exercise of warrants. With this and the current war chest of funds, CEO Anthony Cataldo explained that GT has “approximately $40 million in our treasury, and we are ready to execute on our plan to bring real, positive change to cancer patients around the world. Our initial drug candidate GTB-3550 is achieving phenomenal results in its FDA clinical trial, and we are looking forward to bringing additional drug candidates into trials very soon.”

The company’s robust pipeline also includes candidates for lung and lymphoma cancers (GTB-4550), GTB-5550 for ovarian and prostate cancer, and GTB-6550 for breast and gastric cancer, among other drug candidates. Year-to-date, GTBP stock is up more than 60%, with 3 analysts placing Buy ratings and price targets ranging between $25 and $26.


Fate Therapeutics (NASDAQ:FATE)

Another one of the companies focusing on NK cell therapy is Fate Therapeutics. The company is working on numerous immunotherapy candidates for patients with cancer. In particular, its pipeline treatments aim to become “off-the-shelf treatments or, for lack of a better term, treatments that can work agnostically for different patients. Fate’s treatment platform is based on its iPSC-derived NK, and T-cell product candidates that it says are “designed to synergize with well-established cancer therapies.”

[Read More] Top Biotech Penny Stocks On Robinhood To Watch This Week

The company’s NK cell therapy, FT538, was initially set to target indications for acute myeloid leukemia. So far, 1 of 3 patients in the first dose-escalation portion of Fate’s FT538 study showed an objective response and complete Leukemic blast clearance in bone marrow. While a 30% success rate would appear “significant,” this study also had 1 patient that completely discontinued the study before completing it because of a failure to respond to the therapy. However, something interesting to note is that Fate’s FT538 iNK cells were studied in targeting tumor cells in prostate cancer. In the same study that FT538 showed some impact when combined with a human protein known as IL-15, once combined with GT Biopharma’s (mentioned above) B7H3 TriKETM, there was an eradication of cancer cells:


Fate Therapeutics’ Oncology Treatment Platform

When it comes to Fate during the second half of the year, there are a few things to take into consideration. The most near-term is what’s set to happen in August. On the 19th, Fate will host a virtual event to highlight interim Phase 1 clinical data from its other pipeline candidates, FT596 and FT516. These treatments target relapsed/refractory B-cell lymphomas.

FT516 is being investigated in a multi-dose Phase 1 clinical trial as a monotherapy for treating acute myeloid leukemia. It’s also being studied in combination with CD20-targeted monoclonal antibodies for treating advanced B-cell lymphoma. The candidate is also in a multi-dose Phase 1 clinical trial in combination with avelumab for treating advanced solid tumors resistant to anti-PDL1 checkpoint inhibitor therapy. Avelumab is commercially known as Pfizer’s (NYSE:PFE) BAVENCIO®.

As far as FT596 is concerned, it’s being investigated in a multi-center Phase 1 clinical trial for treating relapsed / refractory B-cell lymphoma as a monotherapy. It’s also being studied in combination with rituximab – commercially known as Biogen’s (NASDAQ:BIIB) Rituxan – and treating relapsed / refractory chronic lymphocytic leukemia as a monotherapy and combined with obinutuzumab.


Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Finally, Teva Pharmaceuticals is a bit more spread out when it comes to treatment pipelines. While it has exposure to oncology platforms, Teva also develops treatments for other indications.

This week the company reported its second-quarter earnings. Teva saw higher adjusted profit and revenue during the quarter. Kåre Schultz, Teva’s President, and CEO said, “We have performed well in the second quarter, improving our profitability and free cash flow generation. This allowed us to reduce our net debt by an additional $500 million to $22.7 billion, once again demonstrating our commitment to and confidence in our long-term goals. Among our growth drivers, AUSTEDO® sales increased compared to the second quarter of last year, AJOVY® net sales have grown to $70 million worldwide, and our biosimilar Truxima® continues to increase its U.S. market share, reaching 25%.”

[Read More] Top Reopening Penny Stocks to Buy in August 2021? 3 to Watch

AUSTEDO® is the company’s drug used to treat Huntington’s disease, while AJOVY® focuses on migraine reduction. Aside from these candidates, Teva has a large pipeline of additional treatments for a range of indications.

Teva Pharmaceutial’s Oncology Treatment Platform

The company is one of the top 5 global suppliers of oncology treatments on the WHO Essential Medicines List. Teva’s oncology pipeline includes both generic medicines and specialty therapies for treating forms of leukemia and non-Hodgkin’s lymphoma. The company also markets biosimilars with the directive of creating lower-cost treatments. These “biosimilars” are medicine very close in structure and function to a branded biologic drug. Some of its current treatments include Truxima for non-Hodgkin’s lymphoma, Syribo in myeloid leukemia, and Herzuma in early-stage HER2+ breast cancer. There’s also Granix in non-myeloid malignancies, and Bendeka in lymphocytic leukemia, among other drugs.


Are Cancer Stocks On Your List Right Now?

Obviously, there are many more companies developing novel cancer treatments. These are just a few that have seen early progress with bullish reactions in the stock market this year. Given the growing demand for new oncology treatments, better delivery methods, and longer-lasting therapies, there’s a good chance cancer research is here to stay. With this latest series of big news and even bigger M&A activity in 2021, it may be time to have some cancer stocks on your list.


Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. Midam has been paid an additional $200,000 for a period from July 2, 2021, to August 2, 2021. This compensation is payment 5 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer

News Related


The Unstoppable Power of WordPress

I’ve been a professional developer since 2005, which has given me the experience to create just about any custom code I want. Yet, when it comes to real-world business applications, ... Read more »

The best technology and innovation podcasts in Spanish

Do you want to learn more about technology, but don’t know where to start? One of the best options, and easily accessible, is to do it through a podcast . ... Read more »

Hard-working families to be £550 worse-off this year as they're hit by 'triple whammy'

According to the think tank’s latest report, the average low-income family with children could see their income fall by over £20 a week over the next six months. This is ... Read more »

Pensioners 'retired into a very different world' - Britons urged to plan ahead now

The number of centenarians (people aged 90 and over) in the UK rose to its highest ever level in 2020, reaching 15,120 – an increase of almost a fifth from ... Read more »

Edinburgh named one of top UK cities to start a new business after climbing rankings

Edinburgh has been named as one of the top two UK cities outside of London to start a new business. © Edinburgh has climbed four places in the rankings since ... Read more »

Wise shares fall after billionaire founder fined over UK tax violation

Money transfer provider Wise’s share price has fallen after The Telegraph revealed its billionaire chief executive has been fined hundreds of thousands of pounds by HMRC for deliberately defaulting on ... Read more »

KFCC logs W208.9b in H1 net profit despite COVID-19 woes

(KFCC)The Korean Federation of Community Credit Cooperatives, the nation’s leading mutual financial institution, said Tuesday it has managed to post strong profits despite the COVID-19 pandemic. Under the leadership of ... Read more »

Fintech can help check digital frauds, says RBI Deputy Governor Sankar

The Reserve Bank Deputy Governor T Rabi Sankar on Tuesday said that Fintech firms can play a significant role in preventing digital frauds, which has surged during the COVID-19 pandemic ... Read more »

Billionaire founder of Wise fined hundreds of thousands of pounds over UK tax violation

The billionaire chief executive of the money transfer provider Wise has been fined hundreds of thousands of pounds by HMRC for deliberately defaulting on his taxes, The Telegraph can reveal. ... Read more »

[KH Finance Forum] Experts, policymakers discuss blueprint for S. Korea's revolutionary road toward ESG

National Pension Service Chairman and CEO Kim Yong-jin delivers a keynote speech at the Korea Herald Finance and Investment Forum at Four Seasons Hotel Seoul on Tuesday. (Park Hyun-koo/The Korea ... Read more »

[KH Finance Forum] S. Korea to promote ESG policies with support, not regulation: finance minister

Deputy Prime Minister and Finance Minister Hong Nam-ki delivers his congratulatory speech at the second Korea Herald Finance and Investment Forum in Seoul on Tuesday. (Park Hyun-koo/ The Korea Herald)South ... Read more »

Is It time For Vape Businesses To Become More Responsible?

Before opening your own business, it’s crucial to invest time into researching your chosen industry. When it comes to the vaping market, there are several rules and regulations that you’ll ... Read more »

[KH Finance Forum] ‘Integrated strategy, bold investment key to digital transformation success'

Shinhan Financial Group’s Chief Digital Officer Sunny Yi speaks during The Korea Herald Finance and Investment Forum at Four Seasons Hotel in Seoul on Tuesday. (Park Hyun-koo/ The Korea Herald)Successful ... Read more »

[KH Finance Forum] NPS looks to exercise institutional power in Korea's ESG push

National Pension Service Chairman and Chief Executive Officer Kim Yong-jin delivers a keynote speech during The Korea Herald Finance and Investment Forum held in Seoul, Tuesday. (Park Hyun-koo/The Korea Herald)The ... Read more »

[KH Finance Forum] Seoul reignites drive to become world‘s top 5 financial hub

  Seoul Mayor Oh Se-hoon speaks during the Korea Herald Finance and Investment Forum held at Four Seasons Hotel Seoul, Tuesday. The Seoul Metropolitan Government will launch its own investment ... Read more »

Data And Analytics In Healthcare: Addressing the 21st-century Challenges To Advance Public Health

Big data analytics have taken the health enterprise industry by storm, owing to its potential to develop lucrative therapeutics in a short time frame. COVID-19 and several current health situations ... Read more »

Back To School, Not Back To Normal: EdTech Shaping a New Future For Education

I’ve lost count of how many times I’ve heard the term “new normal” over the past 18 months, as many of us have tried to imagine what a post-pandemic world ... Read more »

Bitcoin news - live: BTC price tumbles as China central bank launches crackdown on cryptocurrency

LIVE – Updated at 04:47 © Getty Images/iStockphoto precio de bitcoin último 2021 today.jpg After showing signs of recovery following the announcement from China’s central bank that all crypto-related transactions ... Read more »

‘First thing to do' to tackle your credit score - mistake could affect borrowing potential

© THE MONEY FOX/GETTY Francesca the Money Fox and a credit score Money coach Francesca, aka The Money Fox, spoke with about ways to improve a credit score. In ... Read more »

As China cracks down, foreign companies try to figure out where they fit in

Visitors walk on the Bund in Shanghai, China, on Friday, February 12, 2021.Qilai Shen | Bloomberg | Getty Images BEIJING — Foreign companies are trying to hold on to lucrative ... Read more »

Exports expected to rise 15% in Sept. on chips, autos: poll

This file photo, taken Sept. 9, 2021, shows stacks of containers at a port in Incheon, 40 kilometers west of Seoul. (Yonhap)South Korea’s exports are anticipated to rise 15 percent ... Read more »

William Shatner to Go to Space

Star Trek star William Shatner is headed to outer space — for real this time — according to a report from TMZ. At 90 years old, he’ll be the oldest ... Read more »

Hybrid Learning: The Future Of Education

India’s edtech industry is poised to become a $30-billion space in the next 10 years, said a report released in April this year by transaction advisory firm RBSA Advisors. According ... Read more »

Facebook Halts Creation of 'Instagram Kids'

Amid criticism of its handling of research on the effects of Instagram on children, Facebook is “pausing” the creation of “Instagram Kids.” The new program would create an Instagram experience ... Read more »

FedEx Worker Loses Job After TikTok Rant: 'I Will Not Deliver Your Sh--"

Former FedEx delivery man Vincent Paterno’s posted a TikTok rant that went viral — and resulted in him losing his job.  Robert Nickelsberg | Getty Images In the video, (in which ... Read more »

Facebook Pauses Plans for Instagram for Children

Facebook has paused its plans to create an Instagram for children under 13 after the effort drew pushback from dozens of attorneys general. Adam Mosseri, head of Instagram, said in a blog ... Read more »

Tax evasion, money laundering via shell companies set to get tougher

Using ‘shell’ companies to launder money or dodge tax will become tougher with a tribunal ruling last week shifting the ‘burden of proof’ from the income tax (I-T) department to ... Read more »

Families will need an extra £107 to cover basic bills in 'bleak winter' from October

Higher energy prices, rising food bills and a phased £20 a week cut to Universal Credit will leave families £107 a month worse off from next month. From October, the ... Read more »

Stock futures are flat as investors gauge a spike in bond yields

U.S. stock futures were steady in overnight trading Monday following a rise in bond yields that pressured growth pockets in the market. Dow Jones Industrial Average futures fell just 4 ... Read more »

'Risked it all' Not on the High Street founder recalls moment she feared 'losing home'

She said: “I could always remember it was Christmas and we were funding Not on the High Street through our credit card chequebooks at the time. “I was maybe going ... Read more »

Coinbase dives deeper into banking by letting users deposit paychecks into their accounts

Cryptocurrency exchange Coinbase is going deeper into traditional financial services, allowing users to deposit their paycheck directly into their online account. Coinbase said on Monday that U.S. users will be ... Read more »

Panic sellers during stock market dips are often married men with children

Getty Images |  filadendron Panic selling is common after stock market dips, and it's more likely to happen with certain investors, according to research from the Massachusetts Institute of Technology. ... Read more »

The 'secret ingredients' which could secure a happy later life for Britons

Financial planner Wes Moss knows a thing or two about investing, he’s just written a book called What the Happiest Retirees Know and he says it’s not all about money. ... Read more »

Remote workers may want to check their 2021 tax situation. It could be more complicated than it was last year

10'000 Hours | Getty Images If you've worked remotely at any point this year, you may want to evaluate what that could mean for your 2021 tax return. Although many ... Read more »

Wells Fargo pays $37 million to resolve Justice Department claims it defrauded currency customers

Wells Fargo signage on May 5th, 2021 in New York City.Bill Tompkins | Michael Ochs Archives | Getty Images Wells Fargo paid $37 million to settle a government lawsuit accusing ... Read more »

Free health insurance for jobless workers ends this week. What you need to know

Images By Tang Ming Tung | DigitalVision | Getty Images The federal government's six-month health insurance subsidy for jobless workers through the Consolidated Omnibus Budget Reconciliation Act, or COBRA, will ... Read more »

Stocks making the biggest moves midday: Best Buy, Altice, Occidental, Moderna and more

Read more »

How to Prevent Burnout

Burnout is a common topic these days. Whether you’ve hit the wall juggling pandemic childcare while working from home or just have a general feeling of yuck about the world, ... Read more »

42% of Americans have racked up more credit card debt since Covid-19 began. These tips can help get that under control

Getty Images Covid-19 has triggered unprecedented financial challenges for many individuals and families. Now, one survey shows just where many of them are feeling the pinch — their credit card ... Read more »

Furlough warning as end of scheme set to ‘put savings to the test'

Furlough, or the Coronavirus Job Retention Scheme, has been in place for over a year, protecting the jobs of those who worked for businesses impacted by the ongoing pandemic. With ... Read more »